Literature DB >> 22278250

Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.

Wahala M P B Wahala1, Claire Huang, Siritorn Butrapet, Laura J White, Aravinda M de Silva.   

Abstract

Humans develop polyclonal, serotype-specific neutralizing antibody responses after dengue virus (DENV) infection. Many mouse antibodies that neutralize DENV bind to the lateral ridge or A strand epitopes on domain III of the viral envelope (EDIII) protein. It has been assumed that these epitopes are also the main target of human neutralizing antibodies. Using recombinant dengue serotype 2 viruses with altered EDIII epitopes, we demonstrate that EDIII epitopes are not the main target of human neutralizing antibody.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22278250      PMCID： PMC3302537          DOI： 10.1128/JVI.06871-11

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  33 in total

Review 1.  Dengue.

Authors:  Scott B Halstead
Journal:  Lancet       Date:  2007-11-10       Impact factor: 79.321

2.  A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates.

Authors:  Lisset Hermida; Lídice Bernardo; Jorge Martín; Mayling Alvarez; Irina Prado; Carlos López; Beatriz de la C Sierra; Rafael Martínez; Rosmary Rodríguez; Aída Zulueta; Ana B Pérez; Laura Lazo; Delfina Rosario; Gerardo Guillén; María G Guzmán
Journal:  Vaccine       Date:  2006-02-03       Impact factor: 3.641

3.  Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins.

Authors:  Shee-Mei Lok; Victor Kostyuchenko; Grant E Nybakken; Heather A Holdaway; Anthony J Battisti; Soila Sukupolvi-Petty; Dagmar Sedlak; Daved H Fremont; Paul R Chipman; John T Roehrig; Michael S Diamond; Richard J Kuhn; Michael G Rossmann
Journal:  Nat Struct Mol Biol       Date:  2008-02-10       Impact factor: 15.369

4.  Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization.

Authors:  Annette A Kraus; William Messer; Laura B Haymore; Aravinda M de Silva
Journal:  J Clin Microbiol       Date:  2007-09-05       Impact factor: 5.948

5.  Induction of epitope-specific neutralizing antibodies against West Nile virus.

Authors:  Theodore Oliphant; Grant E Nybakken; S Kyle Austin; Qing Xu; Jonathan Bramson; Mark Loeb; Mark Throsby; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

6.  Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus.

Authors:  Gregory D Gromowski; Alan D T Barrett
Journal:  Virology       Date:  2007-08-23       Impact factor: 3.616

7.  Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus.

Authors:  Gregory D Gromowski; Nicholas D Barrett; Alan D T Barrett
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

8.  Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.

Authors:  Soila Sukupolvi-Petty; S Kyle Austin; Whitney E Purtha; Theodore Oliphant; Grant E Nybakken; Jacob J Schlesinger; John T Roehrig; Gregory D Gromowski; Alan D Barrett; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

9.  Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites.

Authors:  Karin Stiasny; Stefan Kiermayr; Heidemarie Holzmann; Franz X Heinz
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

10.  Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization.

Authors:  Steevenson Nelson; Christiane A Jost; Qinq Xu; Jessica Ess; Julie E Martin; Theodore Oliphant; Stephen S Whitehead; Anna P Durbin; Barney S Graham; Michael S Diamond; Theodore C Pierson
Journal:  PLoS Pathog       Date:  2008-05-09       Impact factor: 6.823
View more
  32 in total

Review 1.  Barriers to preclinical investigations of anti-dengue immunity and dengue pathogenesis.

Authors:  Ashley L St John; Soman N Abraham; Duane J Gubler
Journal:  Nat Rev Microbiol       Date:  2013-05-08       Impact factor: 60.633

2.  Broad and strong: the ultimate antibody to dengue virus.

Authors:  Josefina Coloma; Eva Harris
Journal:  Nat Immunol       Date:  2015-02       Impact factor: 25.606

Review 3.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

Review 4.  Subdominance in Antibody Responses: Implications for Vaccine Development.

Authors:  Gunnar Lindahl
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

Review 5.  Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host.

Authors:  Richard J Kuhn; Kimberly A Dowd; Carol Beth Post; Theodore C Pierson
Journal:  Virology       Date:  2015-03-30       Impact factor: 3.616

6.  Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.

Authors:  Usha K Nivarthi; Nurgun Kose; Gopal Sapparapu; Douglas Widman; Emily Gallichotte; Jennifer M Pfaff; Benjamin J Doranz; Daniela Weiskopf; Alessandro Sette; Anna P Durbin; Steve S Whitehead; Ralph Baric; James E Crowe; Aravinda M de Silva
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

7.  Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope.

Authors:  Luke N Robinson; Kannan Tharakaraman; Kirk J Rowley; Vivian V Costa; Kuan Rong Chan; Yee Hwa Wong; Li Ching Ong; Hwee Cheng Tan; Tyree Koch; David Cain; Rama Kirloskar; Karthik Viswanathan; Chong Wai Liew; Hamid Tissire; Boopathy Ramakrishnan; James R Myette; Gregory J Babcock; V Sasisekharan; Sylvie Alonso; Jianzhu Chen; Julien Lescar; Zachary Shriver; Eng Eong Ooi; Ram Sasisekharan
Journal:  Cell       Date:  2015-07-16       Impact factor: 41.582

8.  Functional analysis of dengue virus (DENV) type 2 envelope protein domain 3 type-specific and DENV complex-reactive critical epitope residues.

Authors:  Trevor J Pitcher; Vanessa V Sarathy; Kiyohiko Matsui; Gregory D Gromowski; Claire Y-H Huang; Alan D T Barrett
Journal:  J Gen Virol       Date:  2014-10-22       Impact factor: 3.891

9.  The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2.

Authors:  Lázaro Gil; Ernesto Marcos; Alienys Izquierdo; Laura Lazo; Iris Valdés; Peris Ambala; Lucy Ochola; Rikoi Hitler; Edith Suzarte; Mayling Álvarez; Prisilla Kimiti; James Ndung'u; Thomas Kariuki; María Guadalupe Guzmán; Gerardo Guillén; Lisset Hermida
Journal:  Immunol Cell Biol       Date:  2014-09-02       Impact factor: 5.126

10.  A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease.

Authors:  Amanda E Calvert; Kandice L Dixon; Joseph Piper; Susan L Bennett; Brett A Thibodeaux; Alan D T Barrett; John T Roehrig; Carol D Blair
Journal:  Antiviral Res       Date:  2016-04-26       Impact factor: 5.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.